Neuland Laboratories (524558) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 revenue declined 32.4% year-over-year to ₹316 crores, mainly due to uneven order flow and subdued specialty GDS business; performance was below expectations, but management maintains a positive outlook for FY26 growth, supported by ongoing investments and cost optimization initiatives.

• EBITDA for the quarter was ₹42.1 crores with a margin of 14.4%; profit after tax was ₹13.7 crores, and EPS stood at ₹10.7.

• Management expects healthy FY26 growth as new capacities and commercial molecules ramp up, with continued investment in talent and capabilities to strengthen CDMO positioning.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, were approved by the Board on July 31, 2025.

• Dr. Ravi Shankar Gopinath appointed as an Additional Independent Director for five years, effective August 1, 2025, pending shareholder approval.

Financial highlights

• Q1 FY26 revenue was ₹316 crores (consolidated: ₹29,275.27 lakhs), down 32.4% year-over-year; EBITDA was ₹42.1 crores (margin 14.4%), and PAT was ₹13.7 crores.

• Gross margin for Q1 was 55.3%, slightly down from 56.1% in FY24.

• Working capital increased to 145 days of sales due to higher inventory; free cash flow was negative ₹66 crores.

• Net debt position is negative ₹165 crores at Q1 FY26 end, compared to negative ₹110.2 crores at Q1 FY25 end and negative ₹228.7 crores at Q4 FY25 end.

• Capex outflow for the quarter was ₹79 crores, with FY26 Capex expected at ₹250–254 crores (60% growth, 40% maintenance).

Outlook and guidance

• Revenue growth is expected to resume on the FY24 base, with strong growth anticipated for FY26 and a 20% CAGR over 3–5 years.

• Management expects healthy growth for FY26, driven by investments and a robust pipeline of commercial and early-stage projects.

• Margins are expected to recover as sales ramp up, though no specific EBITDA margin guidance was provided.

• Commercialization of a new CMS molecule and the Unit 3 production block are key milestones for the year.

• Continued focus on cost optimization and differentiation as a CDMO partner is expected to support long-term growth.